Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price increase of 57.45%. However, over the past six months, we’ve seen a weaker performance of 171.56%. The price of PLX fallen by 13.85% over the last 30 days. And in the last five days, it has surged by 12.98%.
In terms of market performance, Protalix BioTherapeutics Inc had a fairly even. The highest value for the stock in the past year was $2.76 on 04/23/25, and the lowest value was recorded at $0.82 on 08/14/24.
52-week price history of PLX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Protalix BioTherapeutics Inc’s current trading price is 7.25% away from its 52-week high, while its distance from the 52-week low is 260.36%. The stock’s price range during this period has varied between$0.82 and $2.76. The Protalix BioTherapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.02 million for the day, a figure considerably higher than their average daily volume of 0.68 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Protalix BioTherapeutics Inc (PLX) has experienced a quarterly rise of 24.89% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 230.98M and boasts a workforce of 213 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.26, with a change in price of +1.25. Similarly, Protalix BioTherapeutics Inc recorded 623,155 in trading volume during the last 100 days, posting a change of +73.10%.
PLX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for PLX stands at 0.13. Similarly, the long-term debt-to-equity ratio is also 0.09.
PLX Stock Stochastic Average
Protalix BioTherapeutics Inc’s raw stochastic average for the past 50 days is presently 100.00%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 100.00%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 90.85% and 88.24%, respectively.
